SCHEMBL4714655

SCHEMBL4714655

COc1cc2c(cn1)nc(-c1nonc1N)n2C1CC1

nearest known ligand 0.66

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 12/20 0.66
▸ RPS6KA5 O75582 4/20 0.60
▸ RPS6KB1 P23443 9/20 0.60
▸ PRKACA P17612 8/20 0.60
▸ GSK3B P49841 7/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715626 0.86 RPS6KA5 (0.65) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4714229 0.84 ROCK1 (0.68) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL14252576 0.82 RPS6KA5 (0.60) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4716133 0.80 ROCK1 (1.00) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4000937 0.75 ROCK1 (0.62) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4001526 0.75 ROCK1 (0.58) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4716813 0.74 RPS6KB1 (0.59) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL6401655 0.73 RPS6KB1 (1.00) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4714882 0.72 RPS6KB1 (0.53) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B
SCHEMBL4717559 0.71 RPS6KA5 (0.93) ROCK1RPS6KA5RPS6KB1PRKACAGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490367-B1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-07-23 — — EP disclosed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 — — US disclosed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 — — US disclosed
US-7348339-B2 2-(4-amino-furazan-3-yl)-1-ethyl-N-[(2R)-2-morpholinylmethyl]-1H-imidazo[4,5-c]pyridine-7-carboxamide; Mitogen- and Stress-Activated Protein (MSK) and Rho (guanosine triphosphate) 1 or 2 kinase inhibitor; neurodegenerative diaeases; antiinflammatory, anticarcinogenic, antiviral and antibacterial agent GLAXO GROUP LIMITED (GB) 2008-03-25 — — US disclosed
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-09-08 — — US disclosed
EP-1490367-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2004-12-29 — — EP disclosed
WO-2003080610-A1 IMIDAZOPYRIDINE DERIVATIVES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2003-10-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197328-A1 Imidazopyridine derivatives as kinase inhibitors NR4A3, XDH, MAPK8 ROCK1 846/4885RPS6KA5 375/4885RPS6KB1 668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback